Hydrogenuhličitan Sodný B. Braun

Hydrogenuhličitan Sodný B. Braun is a pharmaceutical preparation of sodium hydrogen carbonate marketed by B. Braun. It is supplied as a sterile powder, with the exact concentration not disclosed, and meets EU pharmaceutical standards. The product supplies bicarbonate ions to help correct acid–base disturbances when administered under professional supervision. It is intended for hospital or clinical use and must be prepared according to the manufacturer’s instructions.

Hydrogenuhličitan Sodný B. Braun is used in clinical practice to address conditions that involve metabolic acidosis or low bicarbonate levels.

- Treatment of metabolic acidosis in renal failure or diabetic ketoacidosis. - Management of severe hyperkalemia as part of potassium shifting. - Correction of bicarbonate deficit during large-volume fluid resuscitation. - Prevention of acidosis during cardiac surgery or cardiopulmonary bypass. - Adjunct in certain drug intoxications where alkalinization of urine is required.

Adverse reactions to Hydrogenuhličitan Sodný B. Braun are generally related to its systemic alkalinizing effect, the accompanying sodium load, and the route of administration.

Common: - Nausea or mild vomiting, usually transient. - Abdominal discomfort or a sensation of fullness. - Headache or mild dizziness. - Slight rise in blood pressure due to sodium intake. - Local irritation or pain at the intravenous infusion site. - Transient flushing or warmth sensation.

Serious: - Metabolic alkalosis manifested by elevated blood pH and serum bicarbonate. - Hypernatremia that may cause fluid overload, edema, or hypertension. - Cardiac arrhythmias, particularly in patients with pre‑existing heart disease. - Seizures or neuromuscular irritability in severe alkalosis. - Renal impairment exacerbated by increased bicarbonate load.

When using Hydrogenuhličitan Sodný B. Braun, clinicians should consider several precautionary measures to ensure patient safety.

- Assess baseline arterial blood gases and serum electrolytes before administration. - Use caution in patients with renal insufficiency or chronic kidney disease. - Avoid in individuals with known hypersensitivity to sodium bicarbonate preparations. - Monitor blood pressure and fluid balance during and after infusion. - Adjust dose or discontinue if metabolic alkalosis develops. - Consider the sodium load in patients on a restricted‑sodium diet. - Ensure proper dilution and infusion rate to prevent local vein irritation.

Hydrogenuhličitan Sodný B. Braun can interact with other medications or clinical conditions; awareness of these interactions helps prevent complications.

Avoid: - Concurrent use with strong acids or acidifying agents that may neutralize its effect. - Administration together with calcium or magnesium‑containing antacids that can precipitate insoluble salts. - Co‑administration with loop diuretics in patients at risk of electrolyte imbalance without monitoring.

Use with caution: - Concomitant use of potassium‑sparing diuretics, as rapid shifts in potassium may occur. - Patients receiving intravenous insulin therapy for hyperglycemia, since bicarbonate may affect potassium redistribution. - Use in patients on cardiac glycosides, monitoring for arrhythmias due to electrolyte changes. - Combination with other alkalinizing agents (e.g., tromethamine) may increase risk of metabolic alkalosis.